Supplemental material
Journal of Biomolecular Structure and Dynamics
Volume 36, 2018 - Issue 12
Research Article
Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay
& 
Kemal YelekçiDepartment of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, Fatih, Istanbul34083, TurkeyCorrespondence[email protected]
http://orcid.org/0000-0002-0052-4926
http://orcid.org/0000-0002-0052-4926Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
The emerging role of class II histone deacetylases
Source:
Canadian Science Publishing
NuRD and SIN3
Source:
Elsevier BV
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies
Source:
Elsevier BV
Caco-2 cell permeability assays to measure drug absorption.
Source:
Informa Healthcare
Vorinostat, a possible alternative to metronidazole for the treatment of amebiasis caused by
Source:
(:unav)
Acetylation and deacetylation of non-histone proteins
Source:
Elsevier BV
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
Source:
Springer Nature
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Source:
Springer Science and Business Media LLC
Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
HISTONE DEACETYLASE INHIBITORS IN CANCER THERAPY
Source:
Wiley
Novel Hydroxamate and Anilide Derivatives as Potent Histone Deacetylase Inhibitors: Synthesis and Antiproliferative Evaluation
Source:
Bentham Science Publishers Ltd.
rDock: A Fast, Versatile and Open Source Program for Docking Ligands to Proteins and Nucleic Acids
Source:
Public Library of Science (PLoS)
Histone Deacetylase Inhibitors in Cancer Therapy
Source:
American Society of Clinical Oncology (ASCO)
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
Source:
Future Medicine Ltd
Genetic dissection of histone deacetylase requirement in tumor cells
Source:
Proceedings of the National Academy of Sciences
Prediction of the Corneal Permeability of Drug-Like Compounds
Source:
Springer Nature
The Role of NAD+ Dependent Histone Deacetylases (sirtuins) in Ageing
Source:
Bentham Science Publishers Ltd.
Identification of Potential Plk1 Targets in a Cell-Cycle Specific Proteome through Structural Dynamics of Kinase and Polo Box-Mediated Interactions
Source:
Public Library of Science (PLoS)
Optimization of Caco-2 and HT29 co-culturein vitrocell models for permeability studies
Source:
Informa UK Limited
Molecular Dynamics Simulation Study Explaining Inhibitor Selectivity in Different Class of Histone Deacetylases
Source:
Informa UK Limited
Histone deacetylase inhibitors and cell death
Source:
Springer Science and Business Media LLC
Prediction of aqueous solubility of organic compounds using a quantitative structure–property relationship
Source:
Elsevier BV
Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
Source:
Biomedical Informatics
Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation
Source:
American Chemical Society (ACS)
Isoform-selective histone deacetylase inhibitors
Source:
Royal Society of Chemistry (RSC)
Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling
Source:
Elsevier BV
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Source:
Springer Nature
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.
Source:
American Chemical Society (ACS)
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Source:
Springer Science and Business Media LLC
Comparative Molecular Docking Analysis of Cytoplasmic Dynein Light Chain DYNLL1 with Pilin to Explore the Molecular Mechanism of Pathogenesis Caused by Pseudomonas aeruginosa PAO
Source:
Public Library of Science (PLoS)
Designing potential HDAC3 inhibitors to improve memory and learning
Source:
Informa UK Limited
Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents
Source:
Elsevier BV
Isoform-selective histone deacetylase inhibitors
Source:
Royal Society of Chemistry (RSC)
Identification of Potential Histone Deacetylase1 (HDAC1) Inhibitors using Multistep Virtual Screening Approach including SVM Model, Pharmacophore Modeling, Molecular Docking and Biological Evaluation
Source:
Informa UK Limited
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Source:
Alphamed Press
Romidepsin: a novel histone deacetylase inhibitor for cancer
Source:
Informa Healthcare
Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8
Source:
American Chemical Society (ACS)
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays
Source:
Public Library of Science (PLoS)
Histone deacetylase inhibitors
Source:
Elsevier BV
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Source:
American Association for Cancer Research (AACR)
Design and Synthesis of a Potent Histone Deacetylase Inhibitor
Source:
American Chemical Society (ACS)
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate
Source:
Springer Nature
QSAR-based permeability model for drug-like compounds
Source:
Elsevier BV
Histone deacetylases (HDACs): characterization of the classical HDAC family
Source:
Portland Press Ltd.
Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors
Source:
Hindawi Limited
Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer
Source:
Spandidos Publications
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells
Source:
Elsevier BV
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties.
Source:
American Chemical Society (ACS)
The Rule of Five revisited: applying log D in place of log P in drug-likeness filters.
Source:
American Chemical Society (ACS)
Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity
Source:
American Chemical Society (ACS)
Structure of Prokaryotic Polyamine Deacetylase Reveals Evolutionary Functional Relationships with Eukaryotic Histone Deacetylases,
Source:
American Chemical Society (ACS)
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Source:
Springer Science and Business Media LLC
Estimation of ADME properties with substructure pattern recognition.
Source:
American Chemical Society (ACS)
Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads
Source:
Elsevier BV
Histone deacetylase inhibitors: molecular mechanisms of action
Source:
Springer Nature
Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells.
Source:
Elsevier BV
Chris Lipinski discusses life and chemistry after the Rule of Five
Source:
Elsevier BV
Trials with ‘epigenetic’ drugs: An update
Source:
Wiley-Blackwell
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Source:
American Association for Cancer Research (AACR)
Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing
Source:
Informa UK Limited
Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication
Source:
American Society for Microbiology
Biomarkers for predicting clinical responses to HDAC inhibitors
Source:
Elsevier BV
Virtual screening : an overview
Source:
Elsevier BV
Anticancer activities of histone deacetylase inhibitors.
Source:
Springer Science and Business Media LLC
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast
Source:
Springer Science and Business Media LLC
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Source:
Wiley
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
Source:
Springer Nature
Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly
Source:
Springer Nature
Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening
Source:
Elsevier BV
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Source:
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Linking provided by
